Safety, tolerability, efficacy, and pharmacokinetics of the anti-CD40 antibody iscalimab in patients with primary Sjögren’s syndrome: a multi-center, randomised, double-blind, placebo-controlled, parallel group proof-of-concept study


National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK; Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK (B A Fisher MBBS MD(Res)), F Barone PhD, S J Bowman PhD); Division of Clinical Immunology, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary (A Szanto PhD); NIHR Newcastle Biomedical Research Centre and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK (W F Ng PhD); William Harvey Research Institute, Queen Mary University of London, UK (M Bombardieri MD); Charité Research Organisation GmbH, Berlin, Germany (M G Posch MD); Tufts University, Boston, USA (A S Papas DMD, A M. Farag DMSc); Department of Rheumatology, University Hospital Basel, Basel, Switzerland (T Daikeler MD, B Bannert MD, D Kyburz MD); Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, USA (A J Kivitz MD); Division of Rheumatology, Allergy and Immunology NYU Winthrop Hospital, NYU Long Island School of Medicine, NY, USA (S E Carson MD); University College Hospital, London, UK (Prof D A Isenberg MD); Novartis Institutes for Biomedical Research, Basel, Switzerland (P Espié PhD, D Floch MSc, C Dupuy MSc, X Ren MD, P M Faerber PhD, M Rotte MD, J Milojevic PhD, A Avrameas PhD, M A Valentin PhD, J S Rush PhD, P Gergely MD); Novartis Pharma AG, Basel Switzerland, (A M Wright MSc.); Biometrics Matters Limited, Hamilton, New Zealand (H-U Hockey MSc)
*Contributed equally

#Arwa M. Farag is also affiliated with the Department of Oral Diagnostic Science, Faculty of Dentistry, King AbdulAziz University, Jeddah, Saudi Arabia. Xiaohui Ren and Hans-Ulrich Hockey were employees of Novartis at the time of this study but have since left and are currently working as freelancers. Petra M. Faerber is an employee of Hoffmann-La Roche AG, Basel, Switzerland.

Correspondence to:

Peter Gergely

Novartis Institutes for Biomedical Research

Postfach

CH-4002

Basel, Switzerland

peter.ergely@novartis.com

Running title: Safety, tolerability, efficacy, and pharmacokinetics of the anti-CD40 antibody icsalimab in primary Sjögren’s syndrome

Word count: 4392
Summary

Background

Primary Sjögren’s syndrome (pSS) is an autoimmune disease that presents as dryness of the mouth and eyes due to impairment of the exocrine glands, where currently there are no systemic therapies that have demonstrated efficacy. CD40-CD154 mediated T cell-B cell interactions in pSS contribute to aberrant lymphocyte activation in inflamed tissue leading to sialadenitis and other tissue injury. Therefore, we investigated the role of this costimulatory immune pathway in pSS.

Methods

A multi-center, randomised, double-blind, placebo-controlled, proof-of-concept study including two sequential cohorts was conducted to assess the safety, tolerability, efficacy, and pharmacokinetics of iscalimab (CFZ533), a blocking anti-CD40 antibody in pSS patients, by measuring the change after 12 weeks of treatment in the EULAR Sjögren's syndrome disease activity index (ESSDAI) score compared with placebo (Clinicaltrials.gov identifier: NCT02291029). Cohorts 1 (subcutaneous[SC]) and 2 (intravenous[IV]) underwent a double-blind, placebo-controlled period, where patients were randomised (2:1) to receive either iscalimab or placebo, followed by an open-label period where all patients received iscalimab for an additional 12 weeks.

Findings

AEs were similar between iscalimab treatment and placebo groups and two SAEs were reported to be unrelated to treatment with iscalimab. Furthermore, IV treatment in Cohort 2 resulted in a mean reduction of 5.21 points (95% CI:0.96-9.46; one-sided p=0.009) in ESSDAI score.
versus placebo with some improvements in other pSS relevant outcomes and reductions in
levels of the germinal-center biomarker CXCL13 after 12 weeks of treatment.

**Interpretation**

This is the first randomised, placebo-controlled trial of a new investigational drug for pSS that has met its primary endpoint. Our data suggest a pivotal role of CD40-CD154 interactions in pSS pathology and indicate a therapeutic potential for CD40 blockade in pSS.

**Funding**

Novartis Pharma, AG.
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease that is characterised by progressive multiorgan immune-mediated dysfunction that mainly affects exocrine glands; notably lacrimal and salivary glands. This dysfunction leads to oral and ocular dryness, excessive fatigue, extraglandular manifestations, and an increased risk of lymphoma.\(^1\) Treatment is limited to symptomatic care for dryness and mucosal symptoms. Disease-modifying therapies are used for some extraglandular manifestations, but can lead to adverse effects on the lungs, kidneys, and joints. To date there is no evidence-based, systemic disease-modifying therapy approved for pSS.

Hallmark clinical features include the presence of anti-Sjögren’s-syndrome-related antigen-A (anti-Ro/SSA), with or without anti-Sjögren’s-syndrome-related antigen-B (anti-La/SSB),\(^2\) and focal lymphocytic sialadenitis on labial salivary glands or parotid biopsies. Ectopic lymphoid structures (ELS) resembling germinal-centers (GCs) have also been observed within salivary glands from pSS patients,\(^3\) and have been reported to be colocalised with expression of the B cell-attracting chemokine CXCL13.\(^4\) Recent data have indicated that the presence of salivary gland ELS\(^5\) and increased systemic levels of CXCL13\(^6\) correlates with disease severity, implicating ELS and accompanying B cell hyper-reactivity in pSS pathology.\(^7\)

B cell activation, immunoglobulin class-switching, and GC formation are regulated by various immunological costimulatory pathways, notably CD40-CD154 interactions.\(^8,9\) Reports on the expression of CD154 and CD40 on salivary gland-infiltrating T and B cells respectively,\(^10,11\) suggest that T cell-B cell interactions via this pathway may contribute to sialadenitis and ELS formation and function. Furthermore, data suggest that activated CD154-expressing T cells could facilitate the destruction of salivary gland epithelial cells expressing CD40, potentially affecting salivary gland function.\(^12,13\) Finally, recent data show that inhibition/blocking of the CD40 pathway in mouse models of Sjögren’s syndrome suppresses sialadenitis.\(^14,15\)
Collectively, these data suggest CD40-CD154 interactions may be involved in pSS pathology; however, to date, there is no clinical evidence that supports a pivotal role for this pathway in pSS. If this costimulatory pathway were to be involved, blockade of this pathway in clinically active pSS patients might provide therapeutic benefit. The aim of this double-blind, placebo-controlled trial was therefore, to evaluate the ability of iscalimab (CFZ533), a novel antagonistic and non-depleting, anti-CD40 monoclonal antibody, to provide therapeutic benefit to pSS patients.

METHODS

Study design
An exploratory multi-center, randomised, double-blind, placebo-controlled, parallel group, proof-of-concept study (PoC), composed of three sequential cohorts, was conducted to assess the safety, tolerability, efficacy, and pharmacokinetics (PK) of iscalimab in pSS patients (Clinicaltrials.gov identifier: NCT02291029). After completion of the initially planned Cohorts 1 and 2, the study was amended to include an open-label Cohort 3 with the primary objective of assessing iscalimab dosing regimens on the PK properties. The results of the first two cohorts are presented in this paper. The study was sponsored by Novartis Pharma, AG.

The study including the first two cohorts took place at ten investigational sites from Oct 2014 till February 2017. Sites were University Hospitals Birmingham NHS Foundation Trust, UK; University of Debrecen, Hungary; Newcastle upon Tyne Hospitals NHS Foundation Trust, UK; William Harvey Research Institute, Queen Mary University of London, Barts Health NHS Trust, UK; Charité Research Organisation GmbH, Berlin, Germany; Tufts University, USA; University Hospital Basel, Switzerland; Altoona Center for Clinical Research, USA; Rheumatology, Allergy and Immunology NYU Winthrop Hospital, USA; and University College Hospital, London, UK.
Study site health authorities and review boards approved the study protocol.

Participants

After a four-week screening period, a total of 44 pSS patients were recruited to the two cohorts. Eligible patients were aged 18–75 years, weighed 50–150 kg and fulfilled the 2002 American European consensus group (AECG) diagnostic classification criteria for pSS. Patients had at least moderate systemic disease activity with an ESSDAI≥6, and a stimulated whole salivary flow rate >0 mL/min. Only autoantibody seropositive patients were enrolled, dependent on the presence of either anti-SSA/SSB antibodies or both elevated serum titers of antinuclear antibody (ANA) (≥1:160) and positive rheumatoid factor (RF).

Eligible patients could remain on a stable dose standard-of-care treatment such as hydroxychloroquine, or low dose immunosuppressives (including methotrexate, azathioprine, or corticosteroids up to 10 mg per day [equivalent to prednisolone]). Women of child-bearing potential were required to use highly-effective contraception and were assessed by a pregnancy test throughout the study.

Exclusion criteria included treatment with biologic therapies or strong immunosuppressives (such as cyclophosphamide, rituximab) within six-months prior to enrollment; infection; malignancy; secondary Sjögren’s syndrome; or any significant and uncontrolled concurrent medical condition, e.g. presence of lupus anticoagulant factor, hypertension, or psychiatric conditions. Patients with significant laboratory abnormalities, e.g. total white blood cell count outside the range of 2·0-15·0 x 10⁹/L, platelets <100 x 10⁹/L, hemoglobin <9·0 g/dL, lymphocyte count <0·8 x 10⁹/L, neutrophil count <1·5 x 10⁹/L, or liver abnormalities at screening, were not eligible. Written informed consent was obtained from patients before any assessment.
Baseline characteristics of patients are shown in Table 1.

Randomisation and masking

From 82 patients assessed for eligibility, 44 were assigned computer-generated unique randomisation numbers in ascending, sequential order within cohorts i.e. Cohort 1 (October 2014 to June 2016), then Cohort 2 (December 2015 to February 2017) to ensure treatment assignment was unbiased and concealed from patients and investigator staff. A randomisation list per cohort automated the assignment of treatment arms to randomisation numbers in the specified ratio. An unblinded pharmacist’s sole role ensured patients received the correct medication.

Patients were randomised 2:1 to receive either active drug treatment or placebo to assess the safety, tolerability, PK, and preliminary clinical efficacy of multiple subcutaneous (SC, Cohort 1) or intravenous (IV, Cohort 2) doses of iscalimab. Randomisation was stratified according to baseline intake of oral corticosteroids. Both cohorts comprised a 12-week double-blind, placebo-controlled period which was followed by a 12-week open-label period where all patients received iscalimab, and then follow-up (figure 1). All treatment drugs were identical to ensure treatment identities were concealed.

Procedures

Iscalimab (150 mg lyophilisate) and matching placebo were prepared by Novartis, Switzerland, and supplied to the investigator site as open-labeled bulk medication.

In the double-blind period of Cohort 1, 12 patients were assigned to receive either 3 mg/kg doses of iscalimab or placebo via SC injections at a 2:1 ratio at weeks 0, 2, 4, and 8.
In the double-blind period of Cohort 2, 32 patients were randomised to receive either IV 10 mg/kg doses of iscalimab or placebo at a 2:1 ratio. Cohort 2 study design was identical to Cohort 1.

After the double-blind phase, patients entered an open-label period, in which all patients received their respective active treatment doses at weeks 12, 14, 16, and 20, i.e. 3 mg/kg SC for Cohort 1 and 10 mg/kg IV for Cohort 2. All patients were assessed at the end of the open-label period at week 24 and then entered an eight-week follow-up period assessed at weeks 28 and 32.

During treatment and follow-up periods, PK data were collected to characterise the disposition of iscalimab under saturating or non-saturating conditions, and the contribution of CD40 receptors to the elimination of iscalimab (iscalimab is subject to target mediated disposition).

**Outcomes**

To evaluate the efficacy of iscalimab several disease-relevant outcome-measures recorded changes in physician and patient clinical assessments, including EULAR Sjögren's syndrome disease activity index (ESSDAI), a validated systemic disease activity index used to standarise assessments of systemic complications in clinical trials, and EULAR Sjögren’s syndrome patient reported index (ESSPRI). ESSDAI score is derived from the total weighted scores of 12 organ-specific domains that contribute to disease activity, with each being scored in four levels according to severity, and ESSPRI score is derived from the mean scores of three symptoms; dryness, limb-pain, and fatigue.

The two primary objectives of the study were to: i) assess safety and tolerability of multiple SC injections and IV infusions of iscalimab in pSS patients as measured by adverse events (AEs), and ii) compare the effect of multiple SC injections or IV infusions of iscalimab versus placebo,
on the clinical disease activity of pSS patients by the change of ESSDAI score after 12 weeks of treatment.

Secondary outcome measures included the PK assessment of multiple SC and IV doses of icalimab. Self-reported outcomes in patients were evaluated after 12 weeks, as measured by ESSPRI, the short form health survey (SF-36); a 36-item patient-reported survey of QoL measures, the multidimensional fatigue inventory (MFI); a 20-item patient-reported questionnaire designed to measure forms of fatigue, and a visual analog scale (VAS) that recorded changes in the physician’s and patient’s global assessment of the patient’s overall disease activity.

Assessment of safety and adverse events

Safety, PK, and pharmacodynamic (PD) assessments within 6 and 2 hours following each dose administration, respectively, were conducted and any AEs were documented throughout the study at each treatment visit. Safety assessments included physical examinations, electrocardiograms (ECGs), and standard clinical laboratory parameters such as hematology, blood chemistry (blood alkaline phosphate level, liver function tests, amylase, and lipase levels), complement and B cell hyperactivity markers (levels of C3, C4, cryoglobulin, free lambda and lambda immunoglobulin light chains, and beta2 microglobulin), urinalysis, and coagulation tests. Immunogenicity testing (anti-drug antibodies [ADA]) was performed at pre-dose, during treatment, and follow-up periods.

Pharmacokinetic analysis in clinical study

Free-icalimab plasma concentrations were determined by a standard validated enzyme-linked immunosorbent assay using biotinylated recombinant CD40 bound to streptavidin-coated microtiter plates and detected by a peroxidase-conjugated goat anti-human IgG antibody.
Immunogenicity analysis in clinical study

Presence of anti-iscalimab antibodies in plasma was determined using a validated bridging ELISA-based assay. In a pre-incubation step, biotinylated iscalimab was used for capture, and digoxigenin labelled iscalimab and Fab fragments of a polyclonal anti-digoxigenin antibody conjugated to horseradish peroxidase for detection. Drug interference testing: (i) 250 ng/mL of rabbit polyclonal affinity purified anti-CFZ533 IgG (positive control) could be detected in the presence of up to 20·2 μg/mL of iscalimab, and 500 ng/mL of the positive control could be detected in the presence of up to 45·0 μg/mL of iscalimab. The immunogenicity testing adopted a three-tiered strategy with; a screening assay, a confirmatory assay, and titer assay, as tier 1, 2 and 3, respectively.

Biomarker assessments in clinical study

The biomarker CXCL13 was measured in Cohort 2 using a validated bead-based sandwich immunoassay (Cat# LXSAHM, R&D Systems, Inc., Minneapolis, MN, USA). The dynamic range, defined by the LLOQ and ULOQ, was 32·6 – 2760 pg/mL in human serum.

Serum anti-SSB, anti-SSA 52, and anti-SSA 60 IgG were measured using validated individual commercial in vitro diagnostic medical device (IVD) kits from Orgentec (Cat# ORG509, ORG652, ORG660, ORGENTEC Diagnostika GmbH, Mainz, Germany). The dynamic ranges defined by LLOQ-ULOQ were 1250 – 100000 U/mL in human serum, taking into account the minimal dilution requirement (MRD) of 1:500 for anti-SSB and anti-SSA 52 IgG; and 2500 – 200000 U/mL in human serum, taking into account the MRD of 1:1000 for anti-SSA 60 IgG.
Statistical analysis

For clinical outcomes, mixed models for repeated measures were fitted with factors for treatment group, visit, baseline, and interaction between visit and treatment group. Where possible, an unstructured correlation matrix was assumed to account for correlation within patients. Separate models were fitted for each of the cohorts. At each visit, the mean difference in outcome measure between iscalimab and placebo was calculated together with its 95% confidence interval. The same model was fitted to the log-transformed CXCL13 data. Analysis of covariance adjusting for baseline levels was performed on week 12 salivary flow rates, Schirmer’s test, and auto-antibody measurements. The auto-antibody levels were log-transformed prior to analysis.

The planned sample size for Cohort 1 was 12 patients based on safety considerations. The planned sample size for Cohort 2 was 30 patients based on the primary analysis of ESSDAI. It was pre-specified in the protocol that the primary endpoint would be considered to be achieved only if both of the following two conditions held for the reduction in ESSDAI after 12 weeks treatment in the iscalimab 10 mg/kg IV group (compared to placebo):

1. The reduction vs. placebo is statistically significant at the one-sided 10% significance level and,

2. The reduction vs. placebo is estimated to be at least 5-points in magnitude.

The one-sided 10% alpha level in the first condition was considered an appropriate upper-bound for the false-positive risk for an exploratory study. The second condition was included to ensure that the primary endpoint would only be considered to be achieved if the reduction was highly clinically relevant. The sample size of 30 patients in Cohort 2 was chosen such that there was an 83% chance of achieving the primary endpoint (i.e. meeting both these conditions), assuming a true reduction of seven ESSDAI points compared with placebo, a standard deviation (SD) of five and a drop-out rate of 20%. Eventually, 32 patients in total were recruited in Cohort 2.

Clinicaltrials.gov identifier: NCT02291029.
Role of the funding source

The sponsor, Novartis, had a role in the study design, data analysis, and writing of the report in addition to the authors and investigators. All authors had full access to the data and reviewed and approved the final version of the manuscript. The corresponding author had the responsibility to submit for publication.

RESULTS

Between October, 2014 - February, 2017, a randomised, placebo-controlled PoC study of the blocking and non-depleting anti-human CD40 monoclonal antibody iscalimab was conducted, in pSS patients (figure 1). A total of 82 patients were assessed for eligibility, of which 25 were assessed for Cohort 1 and 57 for Cohort 2. Two patients left the study due to an allergic reaction and skin rash (after completing treatment in the double-blind period of Cohort 1) and one other withdrew consent (after two doses of study treatment in Cohort 2) (figure 2).

In Cohort 1, all patients experienced at least one mild or moderate AE in both the iscalimab treatment group and placebo group. In Cohort 2, however, AE incidence was lower in iscalimab treated patients than placebo with 53% compared to 64%, respectively. These results suggest that iscalimab was well-tolerated (Table 2). Furthermore, no major safety signals were observed during the iscalimab treatment open-label periods of both cohorts.

Although, two serious adverse events (SAEs) were observed during the safety follow-up period (approximately 12 weeks after the last dose of iscalimab) these were considered to be unrelated to iscalimab by the investigator, namely, one case of bacterial conjunctivitis in Cohort 1 and one case of atrial fibrillation in Cohort 2. There were no clinically significant abnormalities in
the laboratory assessments or ECG evaluations, and no B cell or other cytopenia was noted which was consistent with the non-depleting nature of iscalimab.\textsuperscript{16,21}

In Cohort 1, 3 mg/kg SC resulted in mean trough plasma concentrations less than 10 µg/mL (supplementary figure 1, upper panel), significantly lower than expected based on PK data of healthy volunteers in the first-in-human study.\textsuperscript{22}

In Cohort 2 (10 mg/kg IV), mean trough plasma concentrations were above levels previously reported to be sufficient for the suppression of GC development and inhibition of T cell-dependent antigen responses in non-human primates\textsuperscript{16} at approximately 100-200 µg/mL (supplementary figure 1, lower panel).

Consequently, no improvement in ESSDAI was seen in Cohort 1, where the baseline-adjusted reduction from placebo at week 12 was only 0.41 points (95% CI -2.89 to 3.70) (figure 3a, upper panel). However, a reduction in disease activity relative to placebo did meet the pre-specified criterion after four infusions of 10 mg/kg IV iscalimab in Cohort 2 with a baseline-adjusted mean reduction in ESSDAI at week 12 of 5.21 points (95% CI 0.96 to 9.46; one-sided \textit{p}=0.009) (figure 3a, lower panel) (supplementary table 1). Improvements were also seen in clinESSDAI at week 12 for Cohort 2 compared to placebo, where a reduction of 6-10 points (95% CI 1.08 to 11.11) was recorded.

ESSDAI domain results showed the most severely affected domain at baseline - the articular domain, achieved the greatest reduction in ESSDAI score at week 12 (supplementary figure 2) suggesting the articular domain may be associated with disease activity moreso than any other domain.

ESSDAI improvements in the double-blind period of Cohort 2 were sustained in the open-label period in patients who started on iscalimab (figure 3a, lower panel). For example, the reduction in ESSDAI at week 14 was 3.85 points (95% CI -0.43 to 8.12; one-sided \textit{p}=0.038); at week 16 it was 2.57 points (95% CI -0.51 to 5.66; one-sided \textit{p}=0.049); and at week 20 it was 3.77 points.
(95% CI 0.38 to 7.16; one-sided p=0.015) compared to the placebo group that switched to 10 mg/kg IV after week 12. Improvements were also observed in the placebo group after switching to 10 mg/kg IV iscalimab at week 12 (figure 3a, lower panel).

In Cohort 2 the percentages of ESSDAI and ESSPRI responders at week 12 were higher in the iscalimab group than in the placebo group. For ESSDAI, 76% of iscalimab patients achieved ≥3 point reduction compared with 55% of placebo patients. Thirteen (62%) iscalimab patients reduced their ESSDAI to below 5 points compared with four (36%) in the placebo group. For ESSPRI, 62% of iscalimab patients achieved ≥1 point reduction compared with 45% for placebo.

In the placebo-controlled period of Cohort 2, some improvements were observed in secondary outcomes at week 12: mean decrease vs. placebo in ESSPRI was 0.95 (95% CI -0.50 to 2.41) (figure 3b, lower panel), SF-36; mean increase vs placebo in physical and mental component score of 3.83 (95% CI -1.81 to 9.48) and 2.52 (95% CI -4.50 to 9.53), respectively, total MFI; mean reduction vs placebo of 9.83 (95% CI -1.01 to 20.66), and patient- and investigator-assesments using VAS; a mean decrease of 8.14 (95% CI -10.39 to 26.67) and 12.16 (95% CI 2.38 to 21.94), respectively (supplementary figure 3).

Improvements were observed in the 10 mg/kg IV iscalimab group compared with placebo in unstimulated and stimulated salivary flow and in Schirmer’s test. A mean increase vs. placebo in unstimulated salivary flow at week 12 of 0.04 mL/min (95% CI -0.03 to 0.10), in stimulated flow of 0.16 mL/min (95% CI -0.15 to 0.46), and for Schirmer’s test of 8.06 mm (95% CI -1.37 to 17.50) and 9.07mm (95% CI -4.61 to 22.75) for the left and right eye, respectively (supplementary figure 4).

Decreases in CXCL13 serum concentrations after 10 mg/kg IV iscalimab compared to placebo in Cohort 2 (56% reduction in geometric mean vs placebo at week 12; 95% CI 27% to 70% [figure 3c]), followed a similar pattern as the changes in ESSDAI (figure 3a, lower panel).
Maximal decreases in CXCL13 were reached at week 8 (61% reduction vs. placebo) and were sustained to week 24 (31% reduction vs. placebo). In patients who were switched to iscalimab from placebo at week 12, a significant decrease in CXCL13 serum concentrations was seen at week 16 with a slight increase towards the end of the study up to week 24 (figure 3c).

Levels of anti-SSA 52, anti-SSA 60, and anti-SSB IgG levels were increased at baseline in pSS patients compared to age- and gender-matched healthy donors (Table 1). A modest decrease from baseline in anti-SSA 52 IgG levels was observed after four doses of 10 mg/kg IV iscalimab at week 12, but this was similar to placebo. Although decreases from baseline in serum levels of anti-SSA 60 and anti-SSB IgG after 12 weeks of treatment with iscalimab (10 mg/kg IV) were more pronounced compared with placebo, they were not statistically significant (anti-SSA: 20% reduction vs placebo, 95% CI 17% increase to 45% reduction; anti-SSB: 38% reduction vs placebo, 95% CI 19% increase to 68% reduction) (supplementary figure 4).

In Cohort 1, there was no consistent change from screening in the blood levels of RF in iscalimab and placebo arms. In iscalimab treated patients in Cohort 2, RF decreased from a median of 22.7 U/mL at screening to 15.3 U/mL at week 12. In the placebo group, the median decreased from 27.1 to 20.6 U/mL. For ANA, the titers decreased from a median of 640 at screening to 320 at week 12 in the iscalimab group. Median titer levels in the placebo group also decreased from 640 at screening to 240 at week 12.

In the standard assays reflecting complement and B cell hyperactivity including levels of C3, C4, cryoglobulin, free lambda and lambda immunoglobulin light chains, and beta2 microglobulin, no clinically meaningful changes were observed after 12 weeks treatment compared to placebo (data not shown).

During immunogenicity testing, one sample (at Day 225; patient in Cohort 1 treated with iscalimab in the open-label period) was confirmed positive. The presence of ADAs was not associated with any immune-related safety signals.
Research in context

Evidence before this study

We searched Pubmed with no language restrictions, first from Oct 15-21, 2018 and again from May 15-30, 2019 using key words Sjögren’s syndrome, clinical trial, CD40, pathology, germinal center, and CXCL13, to find studies on the pathophysiology and treatment of pSS. To date, a small number of randomised, controlled trials have tested various treatment modalities in pSS, with none of these demonstrating convincing efficacy. A published meta-analysis of 32 trials that evaluated 19 different medications of pSS revealed that none of these demonstrated consistent benefit in xerostomia and keratoconjunctivitis sicca. Previously published results have suggested an association between pSS and CD40-CD154 interactions; for example, ELS formation alongside CD40 and CD154 expression in salivary gland biopsies from pSS patients has been demonstrated. Furthermore, amelioration of sialadenitis and reductions in anti-SSA and SSB autoantibodies in the NOD model of Sjögren’s syndrome following CD40-CD154 blockade have been observed. While an association between the CD40-CD154 pathway and autoimmune diseases such as pSS has been suggested, no clinical trial has assessed the efficacy and safety of any modality that blocks this pathway in pSS patients.

Added value of this study

We opted to run a randomised, placebo-controlled study with iscalimab in patients with clinically active pSS, using ESSDAI to define disease activity (ESSDAI ≥6, reflecting the systemic manifestations of the disease) for both inclusion of patients and for the primary endpoint. This established and validated composite outcome measure is regarded as an acceptable regulatory endpoint for pivotal clinical trials, and has been previously used in other pSS clinical trials. Iscalimab is a fully-human, pathway-blocking, non-depleting, anti-CD40 antibody shown to prolong allograft survival when dosed as a monotherapy in a non-human
Implications of all the available evidence

To date, no drug treatment has resulted in a clinically-meaningful change in systemic complications as measured by ESSDAI. The data here suggest that the novel anti-CD40 antibody iscalimab shows clinically meaningful benefit in patients with pSS.

DISCUSSION

To date, a small number of randomised controlled trials have examined the effects of different treatments in pSS, with none of these demonstrating convincing clinical efficacy.\textsuperscript{23,24}

In the double-blind period of Cohort 2 (10 mg/kg IV), a clinically meaningful reduction in disease activity (measured by ESSDAI) after 12 weeks in patients compared with placebo was observed. The continued reductions observed in ESSDAI after week 12 through to week 32 and the reduction in ESSDAI observed in the placebo group once switched to active treatment at week 12 as shown in figure 3a, suggest iscalimab efficacy in the treatment of patients with pSS.

The articular domain of ESSDAI showed the greatest improvement whilst also being the most severely affected at baseline (supplementary figure 2). This finding warrants further studies on tender and swollen joint counts and DAS-28, to understand the importance of this domain in driving ESSDAI improvements.

Iscalimab plasma concentrations in Cohort 1 are likely the consequence of an efficient target-mediated drug disposition (TMDD) of iscalimab and efficient first-past effect. TMDD is a process in which a substantial proportion of the drug (relative to dose) is bound to its target, affecting the disposition of the drug. TMDD involves the binding of iscalimab to CD40
receptors (CD40R) on the cell surface, which triggers internalization\textsuperscript{16} and subsequent lysosomal degradation of the complex.

The disposition of iscalimab depends on its plasma concentration, interstitial fluid, and lymph circulation, along with CD40R expression, internalization, and turnover rates. When CD40R’s are fully saturated TMDD becomes saturated and the contribution of CD40R’s to the overall clearance of iscalimab is minimal. In Cohort 1, the dosing regimen generated non-saturating conditions, and CD40-mediated clearance was efficient and associated with rapid elimination of iscalimab.

TMDD of iscalimab is illustrated in the PK profiles from Cohort 2 (supplementary figure 1, lower panel). During the follow-up period, the inflection point in the PK profiles (at about 10-20 \(\mu g/mL\)) is a marker of target engagement, and is associated with an increased contribution of CD40R’s to the overall clearance of iscalimab and a faster elimination. This inflection point was associated with a loss of target engagement (total soluble CD40 profiles in plasma – not shown). In Cohort 1 also, total soluble CD40 profiles in plasma (not shown) demonstrated lack of sustained target engagement by iscalimab.

As CD40R’s have been reported to be upregulated on parenchyma in inflamed tissues, the elevated expression of CD40R’s is likely responsible of the rapid elimination of iscalimab and efficient first-pass effect after 3 mg/kg SC.

This is further suggested by improvements in ESSDAI in Cohort 2 where trough plasma concentrations were above 100 \(\mu g/ml\), and suggests a dose-response relationship for iscalimab which is in agreement with the dose-dependent pharmacology seen in non-human primates\textsuperscript{16,25}

Importantly, iscalimab was well-tolerated and the number of AEs for both cohorts was similar to placebo. Furthermore, there was no evidence of cytopenias, injection site reactions, thromboembolic events, or increased risk for infections, which have previously been observed with biologics targeting CD154\textsuperscript{26}.
The clinical efficacy observed with iscalimab suggests that CD40-CD154 signaling is a key pathway associated with underlying pSS pathology. Our recent preclinical data\textsuperscript{15} assumes that the antibody acts by several different mechanisms, including the suppression of ELS formation and function by inhibition of CD40-CD154 interactions in salivary glands; the inhibition of sialadenitis; and reduction of B cell hyper-reactivity. The GC-associated chemokine CXCL13 has previously been shown to be elevated in the sera of some pSS patients\textsuperscript{6,27} and is expressed by infiltrating cells in salivary gland tissue\textsuperscript{28}. When patients in this study were compared with CXCL13 levels obtained from healthy volunteers, CXCL13 levels in some patients were elevated at baseline, but returned to a range similar to untreated healthy volunteers after iscalimab treatment with 10 mg/kg IV\textsuperscript{29}.

Published data on CXCL13 suggest that it may be a biomarker that reflects GC activity and correlates with the extent of salivary gland pathology\textsuperscript{7}. Therefore, the iscalimab-dependent reductions in CXCL13 that preceded clinical improvement observed here, might reflect suppression of the structure and function of GCs, and possibly salivary gland ELS. Given that the individuals in this study also had extraglandular involvement based on their ESSDAI $\geq 6$ scores, the clinical benefit observed with iscalimab may also extend to extraglandular tissues.

In contrast to the significant reductions in CXCL13 levels, we observed no or modest reductions in pSS-associated IgG autoantibodies in iscalimab treated patients. This suggests that CD40-CD154 blockade may be less effective in reducing antibody productions from long-lived plasma cells, a notion consistent with the observation of unaffected serum immunoglobulin levels in preclinical and clinical studies with iscalimab\textsuperscript{16,19}. However, SSA and SSB antibodies are rather diagnostic markers of the disease than pathogeneic factors.

While the B cell depleting agent rituximab has been used in selected cases of pSS, previous clinical studies have reported variable therapeutic benefit\textsuperscript{30}. It is therefore possible that CD40 blockade with iscalimab has additional effects beyond targeting B cell hyper-reactivity in pSS.
This is likely due to involvement of CD40 expressing non-B cell types in pSS pathology, including macrophages and other antigen-presenting cells like dendritic cells. This notion was also supported by recent data showing a reduction in macrophages following therapeutic blockade of CD40-CD154 in the non-obese diabetic mouse-model of Sjögren’s syndrome.\textsuperscript{15} Additionally, iscalimab may be more effective at suppressing the effector functions of pathogenic B cells in tissue than B cell depleting strategies.

Our study was designed as an exploratory Phase 2a trial to provide initial safety and Proof-of-Concept for iscalimab in pSS. However, the study has limitations including the small sample size and many of the improvements seen in the clinical outcomes did not reach statistically significance. Furthermore, our results on the ESSDAI domain level do not allow firm conclusions due to the lack of baseline activity for many domains.

In conclusion, the results of this exploratory clinical trial suggest a pivotal role of CD40-CD154 interactions in pSS pathology. Further studies are warranted that are larger in sample size and longer in duration to confirm that CD40-blockade with iscalimab might show clinically meaningful benefit in patients suffering from pSS.
Contributors

BAF, PE, AMW, XR, PMF, JSR and PG conceived and designed the CFZ533 clinical study. BAF, AS, W-FN, MB, MGP, ASP, AMF, DK, TD, BB, AJK, SEC, DAI, FB and SJB recruited cohort individuals and performed the CFZ533 clinical study. AMW and H-UH conducted the statistical analysis for the CFZ533 clinical study. AA, MR, JM and M-AV performed the biomarker assessments and analyses for the CFZ533 clinical study. PE, DF, and CD performed the PK and ADA analysis for the CFZ533 clinical study. BAF, JSR and PG wrote the manuscript with input and comments from all co-authors.

Declaration of interests

Disclosures for consultancy fees (none of which exceeded $10,000) are made for the following authors: BAF (Novartis, Roche, MedImmune, BMS and Virtualscopics); W-FN (Novartis, GlaxoSmithKline, Abbvie, MedImmune, BMS, Atheneum Partners); MB (GSK, Amgen, MedImmune and UCB); AJK (Sanofi, Pfizer, Roche, and UCB); DAI (EMD and Serono); SJB (AstraZeneca/MedImmune, BMS, Celgene, Eli Lilly, Glenmark, GSK, MTPharma, Novartis, Ono, Takeda, UCB, and XLT Bio); DK (Novartis, Roche, Abbvie, Pfizer, BMS, UCB); PE, DF, CD, XR, PMF, AMW, H-UH, MR, M-AV, JSR, JM, AA, and PG were employees of Novartis at the time of conducting and analysing the studies. All other authors declare no competing financial interests.

Data sharing

Novartis Pharma, AG is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data
provided is anonymised to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Acknowledgements

Novartis Pharma, AG was the funder of this trial. Benjamin A. Fisher and Simon J. Bowman have received support from the National Institute for Health Research (NIHR), Birmingham Biomedical Research Centre, and the NIHR/Welcome Trust Birmingham Clinical Research Facility. We thank the patients who participated in this trial, their families, and the staff members at the trial sites who cared for them; the NIHR Office for Clinical Research Infrastructure (NOCRI); translational research collaboration for joint and related inflammatory disease for their operational support for UK sites; the NIHR Newcastle Biomedical Research Centre and the Newcastle Clinical Research Facility. Medical writing support was provided by Linda Hassanali, PhD of Novartis Ireland Ltd., in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). The funding for this writing support was provided by Novartis.
Figure headings and legends:

Figure 1. Schematic clinical study design
Treatment regimens:
Cohort 1: 3 mg/kg SC iscalimab (or placebo) at Weeks 0, 2, 4 and 8 followed by 3 mg/kg SC iscalimab at Weeks 12, 14, 16 and 20.
Cohort 2: 10 mg/kg IV iscalimab (or placebo) at Weeks 0, 2, 4 and 8 followed by 10 mg/kg IV iscalimab at Weeks 12, 14, 16 and 20.

Figure 2. Trial profile
* The patient who withdrew consent was included in the primary analyses model but, due to discontinuation, only contributed data at the week 2 visit.

Figure 3. Baseline adjusted mean a. ESSDAI, b. ESSPRI and c. CXCL13 levels after administration of different doses of iscalimab or placebo
Mean estimates from the mixed models for repeated measures adjusting for baseline levels (i.e. ‘baseline adjusted means’) are presented along with their associated standard errors. The dotted line indicates the mean estimate for patients who were randomised to the placebo group but, in the open label part of the study, received iscalimab 3 mg/kg SC in Cohort 1 (upper panel) or, 10 mg/kg IV in Cohort 2 (lower panel).

Supplementary Figure 1. Plasma concentrations after administration of different doses of iscalimab
In each cohort, the dark thick lines indicate arithmetic mean profiles in the given treatment group and the light lines indicate the individual profiles. For Cohort 1 and 2, the solid line indicates the mean profile of the patients randomised to iscalimab. The dotted line indicates the mean profile for patients who received iscalimab in the open label part of the trial after being first randomised to the placebo group. Concentrations below the limit of quantification were set to zero and included in the calculation of the arithmetic mean. However, since a logarithmic scale is used, these values are excluded from the plot. Mean values of zero are also omitted from the plot for a similar reason.
Supplementary Figure 2. Involvement of various ESSDAI domains after administration of multiple doses of 10 mg/kg of iscalimab or placebo for 12 weeks
The percentage of patients in each severity category (None, Low, Moderate or High) in each ESSDAI domain is presented by treatment group at baseline (‘B’) and week 12 (‘12’). Note that the patient in the iscalimab 10mg/kg IV group who discontinued early from the study is not included in the calculation of the week 12 percentages. The abbreviations for the ESSDAI domains are: Con = Constitutional; Lym = Lymphadenopathy; Gla = Glandular; Art = Articular; Cut = Cutaneous; Pul = Pulmonary; Ren = Renal; Mus = Muscular; PNS = Peripheral nervous system; CNS = Central nervous system; Hae = Haematological; Bio = Biological.

Supplementary figure 3. Forest plot of baseline adjusted treatment effects of 10 mg/kg iscalimab at Week 12 on clinical endpoints
Treatment differences (iscalimab vs placebo) from the MMRM adjusting for baseline levels (i.e. ‘baseline adjusted means’) are presented along with their associated 95% confidence intervals. Each treatment difference is scaled such that an improvement is plotted towards the positive direction (right hand side). For each endpoint, the vertical dotted line indicates a clinically relevant treatment difference

Supplementary figure 4. Changes in salivary flow, Schirmer’s test, and auto-antibody levels after 12 weeks of treatment with iscalimab
For salivary flow (unstim = unstimulated; stim = stimulated) and Schirmer’s test, the mean differences between iscalimab and placebo is presented along with the 95% confidence intervals. For the auto antibodies, the ratio between iscalimab and placebo is presented along with the 95% confidence intervals. Values below the lower limit of quantification (LLOQ) are imputed in the analyses as LLOQ/2.

Table headings

Table 1. Baseline characteristics of patients with pSS in the clinical study
Table 2. Summary of overall incidence and severity in the placebo-controlled first treatment period, and the most frequent adverse events during the clinical trial, for Cohorts 1 and 2
Supplementary Table 1. Results from statistical analysis of ESSDAI
References


30. Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in
BL=Baseline. EOS=End of Study. SC=Subcutaneous. IV=intravenous. *Each cohort was carried out sequentially

Figure 1: Schematic clinical study design*
25 patients assessed for eligibility for **Cohort 1**

13 patients ineligible

12 patients enrolled and randomized

8 patients assigned to iscalimab 3 mg/kg SC

8 patients completed Period 1

8 patients completed Period 2

8 patients included in primary efficacy analysis

1 discontinued due to allergy/skin rash

4 patients assigned to matching placebo

4 patients completed Period 1

4 patients included in primary efficacy analysis

21 patients assigned to iscalimab 10 mg/kg IV

1 withdrew consent

20 patients completed Period 1

20 patients included in primary efficacy analysis

11 patients assigned to matching placebo

11 patients completed Period 1

11 patients included in primary efficacy analysis

32 patients enrolled and randomized

25 patients ineligible

32 patients included in primary efficacy analysis

20 patients completed Period 1

20 patients included in primary efficacy analysis

11 patients completed Period 2

11 patients included in primary efficacy analysis

1 withdrew consent

20 patients completed Period 1

20 patients included in primary efficacy analysis

11 patients completed Period 2

11 patients included in primary efficacy analysis

**Figure 2. Trial profile**
Figure 3a
Figure 3b

![Graph showing data for Cohort 1 and Cohort 2 over time with various treatment groups.](image)

- **Cohort 1**
  - Double Blind Placebo Controlled
  - Open Label (All Iscalimab)
  - Follow Up

- **Cohort 2**
  - Double Blind Placebo Controlled
  - Open Label (All Iscalimab)
  - Follow Up

**Y-axis:** ESSPRI (Baseline Adjusted Mean ± SE)

**X-axis:** Time Since First Dose (Weeks)

Legend:
- Red: Placebo
- Blue: Iscalimab 3mg/kg SC
- Black: Iscalimab 10mg/kg IV
<table>
<thead>
<tr>
<th></th>
<th>Cohort 1</th>
<th></th>
<th>Cohort 2</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Iscalimab 3 mg/kg SC n=8</td>
<td>Placebo→</td>
<td>Total n=12</td>
<td>Iscalimab 10 mg/kg IV n=21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Iscalimab 3 mg/kg SC n=4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>Mean (SD)</td>
<td>56.4 (12.2)</td>
<td>48.8 (3.3)</td>
<td>53.8 (10.6)</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>34, 72</td>
<td>45, 52</td>
<td>34, 72</td>
</tr>
<tr>
<td>Sex – n (%)</td>
<td>Male</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>8 (100%)</td>
<td>4 (100%)</td>
<td>12 (100%)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>Mean (SD)</td>
<td>66.7 (16.6)</td>
<td>78.7 (11.0)</td>
<td>70.7 (15.6)</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>50.0, 91.1</td>
<td>64.1, 89.1</td>
<td>50.0, 91.1</td>
</tr>
<tr>
<td>Baseline ESSDAI</td>
<td>Mean (SD)</td>
<td>12.0 (3.8)</td>
<td>11.8 (3.9)</td>
<td>11.9 (3.6)</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>7, 17</td>
<td>6, 14</td>
<td>6, 17</td>
</tr>
<tr>
<td>Baseline ESSPRI</td>
<td>Mean (SD)</td>
<td>6.8 (1.9)</td>
<td>7.0 (1.8)</td>
<td>6.8 (1.8)</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>4.0, 10.0</td>
<td>5.0, 9.0</td>
<td>4.0, 10.0</td>
</tr>
<tr>
<td>Ant Nuclear Antibodies</td>
<td>n (%)</td>
<td>8 (100.0)</td>
<td>3 (75)</td>
<td>11 (91.7)</td>
</tr>
<tr>
<td>Anti SSA</td>
<td>n (%)</td>
<td>7 (88)</td>
<td>4 (100)</td>
<td>11 (92)</td>
</tr>
<tr>
<td>Anti SSB</td>
<td>n (%)</td>
<td>7 (88)</td>
<td>3 (75)</td>
<td>10 (83)</td>
</tr>
<tr>
<td>Rheumatoid factor</td>
<td>n (%)</td>
<td>7 (88)</td>
<td>2 (50)</td>
<td>9 (75)</td>
</tr>
<tr>
<td>Concomitant Medications</td>
<td>n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antimalarials</td>
<td>1 (13)</td>
<td>0</td>
<td>1 (13)</td>
</tr>
<tr>
<td></td>
<td>Azathioprine</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Corticosteroids</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Methotrexate</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

n=number of participants. SC=Subcutaneous. IV=Intravenous. ESSDAI=EULAR Sjögren’s Syndrome Disease Activity Index. ESSPRI=EULAR Sjögren’s syndrome patient reported intensity. *Patients with rheumatoid factor above normal are recorded.

Table 1. Baseline characteristics of patients with pSS in the clinical study
<table>
<thead>
<tr>
<th>Cohort 1</th>
<th>Cohort 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iscalimab (3 mg/kg SC) n=8</td>
<td>Iscalimab (10 mg/kg IV) n=21</td>
</tr>
<tr>
<td>Placebo → Iscalimab (3 mg/kg SC) n=4</td>
<td>Placebo → Iscalimab (10 mg/kg IV) n=11</td>
</tr>
<tr>
<td>Total n=12</td>
<td>Total n=32</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Placebo-controlled first treatment period</th>
<th>Patients with AEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>34, 7 (88)</td>
</tr>
<tr>
<td>Iscalimab</td>
<td>17, 4 (100)</td>
</tr>
<tr>
<td>Total</td>
<td>51, 11 (92)</td>
</tr>
</tbody>
</table>

- **AEs of Mild intensity**
  - Placebo: 29, 6 (75)
  - Iscalimab: 14, 3 (75)
  - Total: 43, 9 (75)

- **AEs of Moderate intensity**
  - Placebo: 5, 3 (38)
  - Iscalimab: 2, 1 (25)
  - Total: 7, 4 (33)

- **AEs of Severe intensity**
  - Placebo: 0, 0 (0)
  - Iscalimab: 1, 1 (8)
  - Total: 1, 1 (8)

- **Study drug-related AEs**
  - Placebo: 11, 3 (38)
  - Iscalimab: 0, 0 (0)
  - Total: 11, 3 (38)

- **Serious AEs**
  - Placebo: 0, 0 (0)
  - Iscalimab: 0, 0 (0)
  - Total: 0, 0 (0)

- **AEs leading to discontinuation of study treatment**
  - Placebo: 0, 0 (0)
  - Iscalimab: 0, 0 (0)
  - Total: 0, 0 (0)

- **Study drug related AEs leading to discontinuation of study treatment**
  - Placebo: 0, 0 (0)
  - Iscalimab: 0, 0 (0)
  - Total: 0, 0 (0)

**Most frequent adverse events during the clinical trial**

<table>
<thead>
<tr>
<th>Patients with AE(s)</th>
<th>8 (100%)</th>
<th>4 (100%)</th>
<th>12 (100%)</th>
<th>11 (52%)</th>
<th>7 (64%)</th>
<th>18 (56%)</th>
</tr>
</thead>
</table>

**Preferred term**

| Upper respiratory tract infection, nS (%) | 2 (25%) | 2 (50%) | 4 (33%) | 2 (10%) | 2 (18%) | 4 (13%) |
| Headache, nS (%) | 0 (0) | 1 (25) | 1 (8) | 2 (10) | 1 (9) | 3 (9) |
| Nasopharyngitis, nS (%) | 0 (0) | 0 (0) | 0 (0) | 2 (18) | 2 (6) |
| Arthralgia, nS (%) | 2 (25) | 1 (25) | 3 (25) | 0 (0) | 1 (9) | 1 (3) |
| Diarrhoea, nS (%) | 1 (13) | 1 (25) | 2 (17) | 2 (10) | 1 (9) | 3 (9) |
| Rash, nS (%) | 2 (25) | 1 (25) | 3 (25) | 1 (5) | 1 (9) | 2 (6) |
| Dizziness, nS (%) | 2 (25) | 1 (25) | 3 (25) | 1 (5) | 0 (0) | 1 (3) |
| Lower respiratory tract infection, nS (%) | 2 (25) | 1 (25) | 3 (25) | 0 (0) | 0 (0) |
| Urinary tract infection, nS (%) | 2 (25) | 0 (0) | 2 (17) | 0 (0) | 0 (0) | 0 (0) |
| Nausea, nS (%) | 1 (13) | 1 (25) | 2 (17) | 1 (5) | 0 (0) | 1 (3) |
| Toothache, nS (%) | 1 (13) | 1 (25) | 2 (17) | 1 (5) | 0 (0) | 1 (3) |
| Vomiting, nS (%) | 2 (25) | 0 (0) | 2 (17) | 1 (5) | 0 (0) | 1 (3) |
| Contusion, nS (%) | 0 (0) | 0 (0) | 0 (0) | 2 (10) | 1 (9) | 3 (9) |
| Bronchitis, nS (%) | 0 (0) | 0 (0) | 0 (0) | 1 (9) | 1 (3) |
In the grouping by MedDRA preferred terms, only adverse events that occurred in more than 1 patient within at least one cohort are presented. Preferred terms are sorted by total number of AEs across all cohorts. n=number of patients studied. nE=number of AE events in the category. nS=number of patients with at least one AE in the category. % is based on the number of patients. SC=Subcutaneous. IV=Intravenous.

Table 2 Summary of overall incidence and severity in the placebo-controlled first treatment period, and the most frequent adverse events during the clinical trial, for Cohorts 1 and 2

<table>
<thead>
<tr>
<th>Condition</th>
<th>Cohort 1 nS (%)</th>
<th>Cohort 2 nS (%)</th>
<th>Cohort 3 nS (%)</th>
<th>Cohort 4 nS (%)</th>
<th>Cohort 5 nS (%)</th>
<th>Cohort 6 nS (%)</th>
<th>Cohort 7 nS (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constipation</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (9)</td>
<td>1 (3)</td>
<td></td>
</tr>
<tr>
<td>Iron deficiency anaemia</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (5)</td>
<td>1 (9)</td>
<td>2 (6)</td>
<td></td>
</tr>
<tr>
<td>Lipase increased</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (5)</td>
<td>1 (9)</td>
<td>2 (6)</td>
<td></td>
</tr>
<tr>
<td>Photosensitivity reaction</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (5)</td>
<td>1 (9)</td>
<td>2 (6)</td>
<td></td>
</tr>
<tr>
<td>Dehydration</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Injection site haematoma</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Dehydration</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Oral herpes</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Peripheral swelling</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
</tbody>
</table>